# OxSonics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oxsonics

- Industry: Medical Devices & Equipment
- Headquarters: London, UK
- Website: www.oxsonics.com
- Total disclosed funding: $16M
- Latest round: Series B (Jan 9, 2017)
- Investors on record: 6

## About

OxSonics Ltd is a biotechnology company focused on revolutionizing cancer treatment with its proprietary SonoTran® drug delivery platform, enhancing the effectiveness of chemotherapy through innovative ultrasound technology.Founded in 2013 in London, UK, OxSonics Ltd specializes in advanced drug delivery for oncology. The company has seen significant investment activity with its most recent funding round occurring on January 9, 2017, where it raised GBP 9.4 million in SERIES B funding. The founders include Christian Coviello, Colin Story, and Constantin Coussios, with Colin Story currently serving as CEO. OxSonics has participated in 3 deals to date, reflecting its strategic partnerships in the biotech sector.OxSonics Therapeutics specializes in advancing cancer treatment through its proprietary drug delivery platform, SonoTran®. This innovative technology enhances the penetration and distribution of oncology drugs within solid tumors, addressing a significant limitation in current cancer therapies. SonoTran® utilizes ultrasound-activated particles that are co-administered with anti-cancer drugs, creating a localized pumping effect that facilitates deeper drug delivery throughout tumor tissue. The platform is designed to work with existing and novel therapies, making it drug agnostic and applicable across a wide range of solid tumor types. OxSonics primarily targets the oncology sector, collaborating with pharmaceutical and biotech companies to bring its solutions to healthcare providers and patients in key markets, including the United Kingdom and other regions engaged in advanced cancer research and treatment.In the most recent fiscal year, OxSonics generated revenue of GBP 19,599.20. The company reported an EBITDA loss of GBP 458,588.80. OxSonics Therapeutics generates revenue through strategic partnerships and clinical collaborations with pharmaceutical and biotech companies, focusing on the development and deployment of its SonoTran® technology. These collaborations typically involve licensing agreements or co-development arrangements where the company provides its technology for use in combination with various anti-cancer therapies. The revenue structure is primarily B2B, as OxSonics partners with larger healthcare entities that aim to enhance their treatment offerings.In January 2017, OxSonics Ltd raised GBP 9.4 million in SERIES B funding, which will be used to support the growth of OxSonics and its sister company OrthoSon Limited. The company aims to enhance its SonoTran® technology to develop new products aimed at improving cancer treatment efficacy. Additionally, OxSonics plans to expand into new markets, specifically targeting regions with a growing need for advanced cancer therapies. The recent funding will play a pivotal role in facilitating these expansions and innovations.

## Funding rounds

- Series B, Jan 9, 2017, $12M — Oxford Technology Management, Winton Capital, University of Oxford, Longwall Ventures, Perivoli Innovations
- Series A, Jan 17, 2014, $4.5M — Longwall Ventures, Technikos

## Investors

- Longwall Ventures (https://capitalatlas.ai/funds/longwall-ventures) — Series A, Series B
- Technikos (https://capitalatlas.ai/funds/technikos) — Series A
- Oxford Technology Management (https://capitalatlas.ai/funds/oxford-technology-management) — Series B
- Winton Capital (https://capitalatlas.ai/funds/winton-capital) — Series B
- University of Oxford — Series B
- Perivoli Innovations (https://capitalatlas.ai/funds/perivoli-innovations) — Series B